Pricing Log in Create free account
Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue
−1.90%
EPS
−47.2%
Free cash flow
−30.3%
Total debt
−0.43%

Quarter to September 2026, against a year earlier

42.12 0.34 +0.81%
Market cap
$48.7B
P/E
92.6×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. (TEVA) valuation and DCF model

What the price implies · reverse DCF

At $42.12 the price implies free cash flow after share-based pay growing 18.7% a year for ten years.

Free cash flow after share-based pay grew −19.1% a year over the last ten years, 14.0% over the last five. The price asks for 37.8 points a year more than its ten-year rate. The industry’s median company is priced for 11.9%.

In December 2017 the price assumed 1.9% a year; Teva Pharmaceutical Industries Ltd. went on to grow free cash flow after share-based pay −17.3% a year to FY2025.

Price implies
18.7%
Last 5 years, reported
14.0%
Last 10 years, reported
−19.1%
Industry median implies
11.9%

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
The price needs
18.7% a year for ten years
$42.12
today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record Teva Pharmaceutical Industries Ltd.’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to September 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

Today’s price implies free cash flow after share-based pay growing 18.7% a year for ten years.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
Free cash flow Revenue and margin
negative is net cash
new shares the cash flow does not pay for

Against Teva Pharmaceutical Industries Ltd.’s own cost of capital: risk-free 4.3% + beta 0.97 × equity premium 4.5% = 8.7% cost of equity; weighted, 8.7%.

Use 8.7%
Equity value $(4.47b) ▼ below market cap $49.38b
Base case value per share $(3.81) equity value ÷ 1.17b shares
Current price $42.12 market price per share
Below today’s price 109.0% downside at the base case’s assumptions

How we got there$4.83b 10 years of cash to equity+$3.34b terminal value−$12.63b net debt=$(4.47b) equity value÷1.17b shares=$(3.81) per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Drug Manufacturers Specialty & Generic).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E 92.59× 168.99× 168.99× 45% below 20.55× 351% above
P/FCF 36.64× 24.20× 18.13× 102% above 16.29× 125% above
P/B 6.09× 3.59× 2.25× 171% above 1.79× 241% above
EV/EBITDA 26.25× 17.82× 18.68× 41% above 12.22× 115% above
EV/Sales 3.56× 2.50× 2.30× 54% above 2.87× 24% above
P/E P/FCF P/B EV/EBITDA EV/Sales
11.70×16.72×21.74×26.76×10Y avg 18.68×20162018201920212023202420252026

TEVA trades at 26.25× EV/EBITDA, against a 10-year average of 18.68× (range 9.99×–27.87×). That is dearer than 86% of the last 7 year-end readings; re-rating to the average implies $26.86 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.